"Our Smiles" Program
|
Join Our Mailing List
Receive the latest JKF news and event updates.
Email Address:
|
Our Mission
The Joshua Kahan Fund is fighting to cure pediatric leukemia and improve the quality of life for pediatric cancer patients and their families. It raises funds to advance carefully selected, scientific research projects, while perpetuating Josh's name and memory through all of its actions.
"Over the past 5 years, The Joshua Kahan Fund has become the fastest growing philanthropic organization dedicated to advancing the mission of the Division of Oncology at The Children's Hospital of Philadelphia"
Gerrett M Brodeur, MD
The Division of Oncology Children's Hospital of Philadelphia
|
|
JKF Headlines
|
In 2007, we made our largest donation since the inception of our Fund. We committed to donate $1,000,000 to The Children’s Hospital of Philadelphia to create something that has never been done before; an endowed Research Chair solely dedicated to finding a cure for pediatric leukemia. Our donation was deemed so important that Children’s Hospital themselves agreed to donate an additional $1,000,000. This $2,000,000 endowment is unprecedented. Once completed The Joshua Kahan Pediatric Leukemia Research Chair will have continual funding to support high quality, state of the art research objectives at one of the best children’s hospital in world. It is our belief that funding like this will give doctors and scientists more tools than ever before and will undoubtedly help us find a cure for pediatric leukemia. |
|
Action news story on 1 million dollar donation presented at 10th Anniversary Dinner Dance for Joshua Kahan Pediatric Leukemia Research Chair. |
|
News Story from The Early Show the 2nd Annual Prom at the Children's Hospital of Philadelphia |
Learn about the Fund and How You Can Help
 |
You can join us in our effort to fight to cure pediatric leukemia by making a contribution of $25, $50, $100 or whatever you can afford to support our work at The Joshua Kahan Fund.
Donations can be made directly, in honor of someone special, or in memory of a loved one or friend. A special card will be sent in recognition of your gift.
Please fill out the appropriate information. If you need help, please contact us for assistance.
The Joshua Kahan Fund, Inc. is a New Jersey nonprofit corporation. The Fund is a public charity exempt from federal income tax under Section 501 (c)(3) of the Internal Revenue Code.
|
|
|
Leukemia News
-
Researchers found that administering a common chemotherapy drug before bone tumors took root actually fertilized the bone marrow, enabling cancer cells, once introduced, to seed and grow more easily.
-
A study has identified microRNA-3151 as a new independent prognostic marker in patients with acute myeloid leukemia that has normal-looking chromosomes. High levels of this microRNA in cancer cells indicates patients will experience shorter remissions and survival periods. Additionally, the microRNA is encoded within a gene called BAALC, which itself is an independent marker of poor survival when overexpressed in these patients.
-
Multiple myeloma is a form of cancer where the plasma cells in the bone marrow grow out of control, causing damage to bones as well as predisposing patients to anemia, infection and kidney failure. Unfortunately, multiple myeloma continues to progress even after a transplant. A new study now offers promising news about a new long-term therapy, lenalidomide, that can be used after transplantation to slow down the progression of the disease.
-
Medical researchers report significant time-to-progression benefit as well as survival benefit for patients who took maintenance doses of lenalidomide following stem-cell transplant.
Events
Sponsors
Send a Smile
|